This trial has completed recruitment on this platform, and is no longer accepting new referrals.
A research study conducted by Moderna is testing an investigational vaccine that may protect people from RSV. RSV is a common cause of respiratory tract infection and may cause severe disease like pneumonia, especially in younger children and older adults.
Trial ID: NCT04528719
The mRNA-1345-P101 study is evaluating the safety and immune response of an investigational vaccine, called mRNA-1345, to protect against RSV.
Globally, RSV is responsible for millions of lower respiratory tract infections and hospitalizations. In Asia, RSV is reported to be a common cause of respiratory tract infections. Despite this high disease burden, there is limited information on RSV in Asia. By including participants of Japanese descent in this clinical trial, we can better understand RSV in this population and enable further research globally.
Participation in the mRNA-1345-P101 study lasts approximately six months and includes one phone call and up to nine visits to the study site.
Insurance is not needed to join this clinical trial, and compensation for the participants time will be provided.
You will need to travel to one of the study clinics taking part in this clinical trial. Sites are located in: